As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2022 about Considerations for the Use of Real-world Data and Real-World Evidence To Support Regulatory Decision-making for Drug and Biological Products can be found below.